Compare KMT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | NRIX |
|---|---|---|
| Founded | 1938 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 1994 | 2020 |
| Metric | KMT | NRIX |
|---|---|---|
| Price | $29.66 | $25.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $36.00 | $30.50 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 268.33 | N/A |
| EPS | ★ 4.42 | N/A |
| Revenue | ★ $2,356,698,000.00 | $76,987,000.00 |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $7.57 | $48.05 |
| P/E Ratio | $6.75 | ★ N/A |
| Revenue Growth | 19.82 | ★ 99.31 |
| 52 Week Low | $20.35 | $8.20 |
| 52 Week High | $43.81 | $28.23 |
| Indicator | KMT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 46.11 |
| Support Level | $28.40 | $24.95 |
| Resistance Level | $31.15 | $28.23 |
| Average True Range (ATR) | 0.84 | 1.03 |
| MACD | 0.16 | -0.20 |
| Stochastic Oscillator | 40.66 | 30.60 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.